Author: devcuration

Cast AI was born in 2019 from a very specific kind of frustration. The kind that shows up when smart operators scale fast, ship hard, and then watch cloud bills outpace revenue. Yuri Frayman, Laurent Gil, and Leon Kuperman had already built and exited Zenedge to Oracle, so this was not theory. This was lived experience. Kubernetes promised efficiency. Reality delivered waste. Instead of dashboards and suggestions, they built automation that acts. No tickets. No waiting. No humans babysitting infrastructure at 2 a.m. Cast AI secured a strategic investment from Pacific Alliance Ventures, the U.S. venture arm of Shinsegae Group,…

There are funding announcements, and then there are moments when biology clears its throat and reminds the market who has been doing the real work. Cytotheryx, Inc. just closed a $60M Series A led by Ouroboros Family Founders Fund I, LP, with complementary debt financing from QRS Investments, LLC. Preclinical on paper, inevitable in reality. This is not noise. This is timing earned the hard way. Cytotheryx, Inc. did not show up overnight with a logo and a mission statement. The science traces back more than 20 years, starting at Oregon Health and Science University, moving through Mayo Clinic, and…

There is a quiet truth in oncology that never makes the press releases. Most cancer care does not happen in glass towers tied to academic prestige. It happens in community clinics where complexity shows up early, data shows up late, and decisions still have to be right the first time. VieCure was built for that reality, not the brochure version. Founded in 2015, VieCure did not chase noise. Brian Leyland-Jones and Fred Ashbury built it because precision medicine exploded faster than the systems meant to support it. Hundreds of therapies, diagnostics, biomarkers, and clinical pathways landed on clinicians already stretched…

AI4Eyes Medical Technologies has been operating with the patience of people who understand that credibility in medtech is earned, not announced. Built between Montreal and Vancouver, this AI-driven medical device company is focused on ocular diagnostics, a corner of healthcare where speed, accuracy, and consistency decide outcomes long before marketing ever gets a vote. Eyecare has lived with fragmented workflows, stacked devices, and slow feedback loops for years. AI4Eyes did not try to polish that system. They condensed it until it finally made sense. In Q4 2025, AI4Eyes Medical Technologies secured $6.5M CAD through a disciplined internal financing round. $3.7M…

Ventaris Surgical just dropped a clean $30M Series A, and anyone who understands kidney stone procedures knows why this matters. Stones get fragmented, fragments get left behind, and patients end up starring in a sequel nobody wanted. This round is about finishing the job, not celebrating partial wins. Longitude Capital led it with conviction, Vensana Capital stepped in with serious intent, and Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners stayed involved because progress like this is earned in the OR, not manufactured in slides. Ventaris Surgical was formed in April 2024 by people who already learned the hard lessons.…

Nanochon just did something quiet, surgical, and expensive in the way real progress usually is. A $4.1M oversubscribed Seed Prime II round closed, total capital now at $11.3M, and nobody involved is pretending this is about noise. This is about knees, physics, biology, and patience. The kind that does not fit neatly into quarterly updates but shows up years later in how someone walks, runs, or climbs stairs without thinking about it. Founded in 2016 by Benjamin Holmes, Ph.D. and Nathan J. Castro, Ph.D., Nanochon started when two biomedical engineers at George Washington University decided cartilage deserved more than temporary…

Orca Bio did not wake up one morning and decide to chase $250M. This was eight years of precision thinking, Stanford-rooted science, and an almost unreasonable refusal to accept how broken transplant medicine has been for decades. Founded in 2016 by Ivan Dimov, Nate Fernhoff, and Jeroen Bekaert, Orca Bio started with a blunt reality: patients with blood cancer are often forced to choose between relapse and graft-versus-host disease, and that is not medicine, that is math without empathy. The answer became Orca-T, a high-precision allogeneic cell therapy built with the discipline of a watchmaker instead of the chaos of…

There is something fitting about a company named Locus choosing to work exactly where the pressure converges. Not the headlines, not the chatter, but the precise point where biology, urgency, and consequence collide. Locus Biosciences secured a $3.3M NIAID contract, expandable to $28M, and the announcement lands less like celebration and more like confirmation. This is what it looks like when focus compounds. Born in Morrisville, North Carolina and spun out of North Carolina State University in 2015, Locus Biosciences was never designed to be polite. The foundation was CRISPR-Cas3, licensed straight from academia and engineered to destroy bacterial DNA,…

$140M. Series D. $1.2B valuation. Torq did not wander into unicorn territory by accident. It showed up early, stayed late, and understood the assignment before most people finished the slide deck. Founded in Jan 2020 by Ofer Smadari, Leonid Belkind, and Eldad Livni, this is what happens when founders who already built and sold a cybersecurity company for ~$250M decide the problem is still broken and the industry still owes customers better answers. Security Operations Centers have been running a marathon on a treadmill for years. Thousands of alerts a day, real threats buried under noise, analysts burning cognitive fuel…

MEDIPOST Inc. just put $140M on the board without pounding the table. January 9, 2026 is one of those dates biotech will quietly circle and come back to later. Parent company MEDIPOST Co., Ltd. secured capital to move allogeneic umbilical cord blood-derived stem cell therapies deeper into late-stage clinical reality. No noise, no slogans. Just money aimed directly at inflammation-driven degeneration and the long game of fixing it. This didn’t start in Cambridge, Massachusetts. It started June 26, 2000 in Seoul. Yoon-Sun Yang, MD PhD, building something real while practicing medicine at Samsung Medical Center, later joined by Won-Il Oh,…